dc.contributor.author
Efsen, Anne Marie W.
dc.contributor.author
Schultze, Anna
dc.contributor.author
Miller, Robert F.
dc.contributor.author
Panteleev, Alexander
dc.contributor.author
Skrahin, Aliaksandr
dc.contributor.author
Podlekareva, Daria N.
dc.contributor.author
Miró Meda, José M. (José María), 1956-
dc.contributor.author
Girardi, Enrico
dc.contributor.author
Furrer, Hansjakob
dc.contributor.author
Losso, Marcelo H.
dc.contributor.author
Toibaro, Javier
dc.contributor.author
Caylà i Buqueras, Joan A.
dc.contributor.author
Mocroft, Amanda
dc.contributor.author
Lundgren, Jens D.
dc.contributor.author
Kirk, Ole
dc.contributor.author
Post, Frank A.
dc.contributor.author
Manzardo, Christian
dc.contributor.author
Ligero, M. C.
dc.contributor.author
González, J.
dc.contributor.author
HIV study in EuroCoord
dc.date.issued
2019-04-03T14:18:23Z
dc.date.issued
2019-04-03T14:18:23Z
dc.date.issued
2019-04-03T14:18:23Z
dc.identifier
https://hdl.handle.net/2445/131299
dc.description.abstract
Objectives: Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce. Methods: In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral therapy (ART). Results: A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5-74.1) of MDR-TB patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was demonstrated in only 23%. Conclusions: Our results show that internationally recommended MDR-TB treatment regimens were infrequently used and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient population and the environment in which health care is provided. Urgent improvement of management of patients with TB/HIV in EE, in particular for those with MDR-TB, is needed and includes widespread access to rapid TB diagnostics, better access to and use of second-line TB drugs, timely ART initiation with viral load monitoring, and integration of TB/HIV care.
dc.format
application/pdf
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1016/j.jinf.2017.10.007
dc.relation
Journal of Infection, 2018, vol. 76, num. 1, p. 44-54
dc.relation
https://doi.org/10.1016/j.jinf.2017.10.007
dc.relation
info:eu-repo/grantAgreement/EC/FP7/260694/EU//EUROCOORD
dc.rights
cc-by-nc-nd (c) The British Infection Association, 2018
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Medicina)
dc.subject
Infeccions per VIH
dc.subject
HIV infections
dc.title
Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB: HIV study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion